12:00 AM
 | 
Mar 24, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cytochrome P450 3A5 (CYP3A5)

Cancer

INDICATION: Pancreatic cancer

Patient sample and mouse studies suggest inhibiting CYP3A5 could help treat drug-resistant pancreatic ductal adenocarcinoma (PDAC). In patient-derived PDAC cell lines, high expression of CYP3A5 in one cell subtype was associated with insensitivity to Tarceva erlotinib, Sprycel dasatinib or paclitaxel, and high expression of CYP3A5 in two other cell subtypes was associated with...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$18 USD
More Info >